BiotechTube
Home/Pipeline/Leap 1121

Leap 1121

Autoimmune disease

PreclinicalActive

Key Facts

Indication
Autoimmune disease
Phase
Preclinical
Status
Active
Company
Ability Biotherapeutics

About Ability Biotherapeutics

AI‑driven platform developer creates conditional, multispecific antibodies for cancer and autoimmune disease.

View full company profile

Therapeutic Areas

OncologyImmunology

Other Autoimmune disease Drugs

DrugCompanyPhase
Fusion ImmunotherapeuticHCW BiologicsClinical Trial
Autoimmune Disease ProgramCarisma TherapeuticsDiscovery
Not Specified (Autoimmune Focus)Narwhal BioPre-clinical
Undisclosed Precision BiologicRhapsogenPre-clinical
First-in-class autoimmune disorder targetGenesis TherapeuticsPre-clinical
GIM-407GeorgiamunePreclinical
Autoimmunity ProgramAccipiter BiosciencesPreclinical
Undisclosed Autoimmune ProgramTianTi BiotherapeuticsPreclinical
Undisclosed Transcription FactorTalus BioscienceDiscovery
AppusBioVectisPre-clinical
ALLO-329Allogene TherapeuticsPhase 1